Drug Trial Radar · NCT07664553
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Jul 8, 2026
Primary completion
May 23, 2028
Study completion May 23, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus (T2DM), treated with a background insulin and other background glucose-lowering medication(s)
Conditions
- Type 2 Diabetes Mellitus
Interventions
ElecoglipronDrug
Elecoglipron is administered orally once daily.
PlaceboDrug
Placebo is administered orally once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Hemoglobin A1c (HbA1c)Time frame: Baseline to Week 40
Locations
132 sites in 13 countries. Site status is shown where the registry gives one.
Research Site
Little Rock, Arkansas · Not yet recruiting
Research Site
Sacramento, California · Not yet recruiting
Research Site
Aurora, Colorado · Not yet recruiting
Research Site
DeLand, Florida · Suspended
Research Site
Doral, Florida · Not yet recruiting
Research Site
Ocoee, Florida · Recruiting
Research Site
Decatur, Georgia · Not yet recruiting
Research Site
Potomac, Maryland · Not yet recruiting
Research Site
Brooklyn, New York · Suspended
Research Site
Cary, North Carolina · Not yet recruiting
Research Site
Morehead City, North Carolina · Not yet recruiting
Research Site
Myrtle Beach, South Carolina · Not yet recruiting
Research Site
Memphis, Tennessee · Not yet recruiting
Research Site
Houston, Texas · Not yet recruiting
Research Site
Round Rock, Texas · Not yet recruiting
Research Site
San Antonio, Texas · Not yet recruiting
Research Site
Renton, Washington · Not yet recruiting
Research Site
Campbelltown, Australia · Not yet recruiting
Research Site
East Toowoomba, Australia · Recruiting
Research Site
Heidelberg Heights, Australia · Not yet recruiting
Research Site
Parkville, Australia · Not yet recruiting
Research Site
St Leonards, Australia · Not yet recruiting
Research Site
Dupnitsa, Bulgaria · Not yet recruiting
Research Site
Kozloduy, Bulgaria · Not yet recruiting
Research Site
Plovdiv, Bulgaria · Not yet recruiting
Research Site
Sofia, Bulgaria · Not yet recruiting
Research Site
Stara Zagora, Bulgaria · Not yet recruiting
Research Site
Veliko Tarnovo, Bulgaria · Not yet recruiting
Research Site
Yambol, Bulgaria · Not yet recruiting
Research Site
Surrey, British Columbia, Canada · Not yet recruiting
Research Site
Vancouver, British Columbia, Canada · Recruiting
Research Site
Brampton, Ontario, Canada · Not yet recruiting
Research Site
North York, Ontario, Canada · Not yet recruiting
Research Site
Sarnia, Ontario, Canada · Not yet recruiting
Research Site
Scarborough Village, Ontario, Canada · Not yet recruiting
Research Site
Toronto, Ontario, Canada · Recruiting
Research Site
Saint-Charles-Borromée, Quebec, Canada · Not yet recruiting
Research Site
Changsha, China · Not yet recruiting
Research Site
Changsha, China · Not yet recruiting
Research Site
Hefei, China · Not yet recruiting
Showing 40 of 132 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.